Litzenburger; Tobias
Patent Applications and Registrations
Patent applications and USPTO patent grants for Litzenburger; Tobias.The latest application filed is for "anti-cd40 antibodies".
- Litzenburger; Tobias - Mittelbiberach DE
- LITZENBURGER; Tobias - Stockdorf DE
- Litzenburger; Tobias - Planegg N/A DE
- LITZENBURGER; Tobias - Newtown CT
| Patent | Date |
|---|---|
| Anti-cd40 Antibodies App 20220153857 - BARRETT; Rachel Rebecca ; et al. | 2022-05-19 |
| Anti-CD40 antibodies Grant 11,242,394 - Barrett , et al. February 8, 2 | 2022-02-08 |
| Anti-psgl-1 Antibodies And Uses Thereof App 20210395383 - Bassarab; Stefan ; et al. | 2021-12-23 |
| Anti-cd40 Antibodies App 20190169301 - Barrett; Rachel Rebecca ; et al. | 2019-06-06 |
| Anti-cd40 Antibodies App 20170058039 - BARRETT; Rachel Rebecca ; et al. | 2017-03-02 |
| Dabigatran antidotes Grant 9,499,633 - Litzenburger , et al. November 22, 2 | 2016-11-22 |
| Anti-cd40 Antibodies App 20160222124 - BARRETT; Rachel Rebecca ; et al. | 2016-08-04 |
| Antibodies For Guanylyl Cyclase Receptors App 20160168251 - WATERMAN; Alisa ; et al. | 2016-06-16 |
| Anti-cd40 Antibodies App 20150315282 - BARRETT; Rachel Rebecca ; et al. | 2015-11-05 |
| Anticoagulant Antidotes App 20150210778 - VAN RYN; Joanne ; et al. | 2015-07-30 |
| Antibodies for guanylyl cyclase receptors Grant 9,090,695 - Waterman , et al. July 28, 2 | 2015-07-28 |
| Polynucleotides encoding anti-CD40 antibodies Grant 9,090,696 - Barrett , et al. July 28, 2 | 2015-07-28 |
| Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Grant 9,034,822 - Van Ryn , et al. May 19, 2 | 2015-05-19 |
| Anticoagulant Antidotes App 20150118225 - LITZENBURGER; Tobias ; et al. | 2015-04-30 |
| Anticoagulant Antidotes App 20140377265 - VAN RYN; Joanne ; et al. | 2014-12-25 |
| Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof Grant 8,821,871 - Van Ryn , et al. September 2, 2 | 2014-09-02 |
| Anti-cd40 Antibodies App 20140179907 - BARRETT; Rachel Rebecca ; et al. | 2014-06-26 |
| Anti-CD40 antibodies Grant 8,591,900 - Barrett , et al. November 26, 2 | 2013-11-26 |
| Anticoagulant Antidotes App 20130289248 - VAN RYN; Joanne ; et al. | 2013-10-31 |
| Anti-psgl-1 Antibodies And Uses Thereof App 20130251708 - BASSARAB; STEFAN ; et al. | 2013-09-26 |
| Anti-psgl-1 Antibodies And Uses Thereof App 20130209449 - Bassarab; Stefan ; et al. | 2013-08-15 |
| Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds Grant 8,486,398 - Van Ryn , et al. July 16, 2 | 2013-07-16 |
| Anti-psgl-1 Antibodies And Uses Thereof App 20130011391 - Bassarab; Stefan ; et al. | 2013-01-10 |
| Anticoagulant Antidotes App 20120276123 - VAN RYN; Joanne ; et al. | 2012-11-01 |
| Antibodies for Guanylyl Cyclase Receptors App 20120114659 - Waterman; Alisa ; et al. | 2012-05-10 |
| Anticoagulant Antidotes App 20120027780 - Van Ryn; Joanne ; et al. | 2012-02-02 |
| Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation App 20110311553 - LITZENBURGER; Tobias ; et al. | 2011-12-22 |
| Anti-cd40 Antibodies App 20110243932 - BARRETT; Rachel Rebecca ; et al. | 2011-10-06 |
| Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation App 20100119506 - LITZENBURGER; Tobias ; et al. | 2010-05-13 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 